Results 1 to 10 of about 4,378 (208)

Extraskeletal osteosarcoma harboring ETV6::NTRK3 fusion treated successfully with larotrectinib: a case study [PDF]

Communications Medicine
Background Extraskeletal osteosarcoma (ESOS) is a rare, aggressive mesenchymal tumor with limited therapeutic options and a poor prognosis due to frequent metastases. Identifying targetable genetic alterations could improve treatment outcomes.
Kristijan Skok, Florian Ochsenhofer, Raphael Gassner, Andreas Leithner, Joanna Szkandera, Christian Viertler, Sonja Hasenschwandtner, Andreas Reichinger, Bernadette Liegl-Atzwanger   +8 more
doaj   +5 more sources

NGF-TrkA Axis Enhances PDGF-C-Mediated Angiogenesis in Osteosarcoma via miR-29b-3p Suppression: A Potential Therapeutic Strategy Using Larotrectinib [PDF]

Life
Angiogenesis plays a critical role in osteosarcoma (OS) growth and metastasis. While nerve growth factor (NGF) is implicated in cancer progression, its role in OS angiogenesis remains unclear.
Sheng-Mou Hou, Ching-Yuan Cheng, Wei-Li Chen, En-Ming Chang, Chih-Yang Lin   +4 more
doaj   +5 more sources

Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma [PDF]

CNS Oncology
A 7-year-old female with recurrent midline pilocytic astrocytoma harboring a rare STRN3::NTRK2 fusion achieved sustained near-complete radiographic and clinical response to larotrectinib, a selective TRK inhibitor.
Kishore Balasubramanian, Kar-Ming Fung, Rene Y. McNall-Knapp, Karl Balsara   +3 more
doaj   +3 more sources

Metastatic SQSTM1-NTRK1 fused non-small-cell lung cancer treated with larotrectinib and stereotactic radiosurgery resulting in durable complete response: a case report [PDF]

Therapeutic Advances in Medical Oncology
Lung cancer is one of the most common malignancies and causes the most cancer deaths in the United States. Targeted therapies have improved the survival of patients with advanced disease. Neurotrophic tropomyosin receptor kinase (NTRK) fusions are a rare
Colton Betts, Ari Kassardjian, Arya Amini   +2 more
doaj   +3 more sources

Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor [PDF]

Frontiers in Oncology
Neurotrophic tropomyosin receptor kinase (NTRK)-rearranged spindle cell tumors are often resistant to chemotherapy and radiotherapy. Fortunately, they are sensitive to targeted therapy of tropomyosin receptor kinase (TRK) inhibitors. However, the data on
Linnan Wu, Linnan Wu, Weiji Xie, Weiji Xie, Juan Wang, Juan Wang, Suying Lu, Suying Lu, Yizhuo Zhang, Yizhuo Zhang, Junting Huang, Junting Huang   +11 more
doaj   +3 more sources

Three locally invasive infantile fibrosarcoma cases treated with larotrectinib

The Turkish Journal of Pediatrics
Background. Infantile fibrosarcoma is a rapidly growing soft tissue tumor, often managed by surgical resection, with chemotherapy and radiotherapy as additional options.
Hikmet Gülşah Tanyıldız, Yasin Yılmaz, Doğa Dalay, Şifa Şahin, Serap Karaman, Ayşegül Ünüvar, Zeynep Karakaş, Deniz Tuğcu   +7 more
doaj   +2 more sources

A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is. [PDF]

Future Oncol
Plain Language Summary What is this summary about? This is a summary of a publication that reported data from participants in two clinical trials that studied a targeted cancer medicine called larotrectinib in a total of 20 participants with TRK fusion ...
Drilon A, Lin JJ, Burcoveanu DI, Ollis C, Reiss M, Torberger O, Moreno V.   +6 more
europepmc   +2 more sources

Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. [PDF]

JCO Precis Oncol
PURPOSE Neurotrophic tyrosine receptor kinase gene fusions are oncogenic drivers of various solid tumors. Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor approved for patients with TRK fusion cancer on the basis of single ...
Brose MS, Westphalen CB, Pan X, Bernard-Gauthier V, Kurtinecz M, Guo H, Aris V, Brett NR, Majdi A, Subbiah V, Pennell NA, Kehl KL, Drilon A.   +12 more
europepmc   +2 more sources

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care. [PDF]

JCO Precis Oncol
PURPOSE Widespread adoption of the tropomyosin receptor kinase (TRK) inhibitor larotrectinib has been hampered by limited comparisons against non–TRK inhibitor standard of care (SoC) regimens because of the rarity of TRK fusions.
Bokemeyer C, Abrams KR, Garcia-Foncillas J, Italiano A, Lassen U, Linsell L, Marian M, Paracha N, Sullivan SD, Brega N, Thompson J.   +10 more
europepmc   +2 more sources

Redifferentiation Effect of Larotrectinib for <i>NTRK</i> Fusion-Positive Pediatric Thyroid Cancer and Outcomes After Therapy. [PDF]

J Endocr Soc
Context Few data exist regarding larotrectinib therapy in pediatric NTRK fusion–positive papillary thyroid cancer (PTC), especially its effects on redifferentiation in radioactive iodine–refractory (RAIR) disease.
Castellanos LE, Yedururi S, Waguespack SG.   +2 more
europepmc   +2 more sources